These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Filippatos G; Anker SD; Böhm M; Gheorghiade M; Køber L; Krum H; Maggioni AP; Ponikowski P; Voors AA; Zannad F; Kim SY; Nowack C; Palombo G; Kolkhof P; Kimmeskamp-Kirschbaum N; Pieper A; Pitt B Eur Heart J; 2016 Jul; 37(27):2105-14. PubMed ID: 27130705 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial. Butt JH; Adamson C; Docherty KF; de Boer RA; Petrie MC; Inzucchi SE; Kosiborod MN; Maria Langkilde A; Lindholm D; Martinez FA; Bengtsson O; Schou M; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV; Køber L Circ Heart Fail; 2021 Dec; 14(12):e008837. PubMed ID: 34802253 [TBL] [Abstract][Full Text] [Related]
13. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside. Kolkhof P; Jaisser F; Kim SY; Filippatos G; Nowack C; Pitt B Handb Exp Pharmacol; 2017; 243():271-305. PubMed ID: 27830348 [TBL] [Abstract][Full Text] [Related]
14. Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. Vaduganathan M; Mentz RJ; Claggett BL; Miao ZM; Kulac IJ; Ward JH; Hernandez AF; Morrow DA; Starling RC; Velazquez EJ; Williamson KM; Desai AS; Zieroth S; Lefkowitz M; McMurray JJV; Braunwald E; Solomon SD Eur Heart J; 2023 Aug; 44(31):2982-2993. PubMed ID: 37210743 [TBL] [Abstract][Full Text] [Related]
15. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760 [TBL] [Abstract][Full Text] [Related]
16. Finerenone Improves Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction Irrespective of Age: A Prespecified Analysis of FINEARTS-HF. Chimura M; Petrie MC; Schou M; Martinez FA; Henderson AD; Claggett BL; Desai AS; Kolkhof P; Viswanathan P; Lage A; Lam CSP; Senni M; Shah SJ; Rohwedder K; Mueller K; Voors AA; Zannad F; Pitt B; Vaduganathan M; Jhund PS; Solomon SD; McMurray JJV Circ Heart Fail; 2024 Nov; 17(11):e012437. PubMed ID: 39342655 [TBL] [Abstract][Full Text] [Related]
17. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. Cunningham JW; Vaduganathan M; Claggett BL; Zile MR; Anand IS; Packer M; Zannad F; Lam CSP; Janssens S; Jhund PS; Kober L; Rouleau J; Shah SJ; Chopra VK; Shi VC; Lefkowitz MP; Prescott MF; Pfeffer MA; McMurray JJV; Solomon SD JACC Heart Fail; 2020 May; 8(5):372-381. PubMed ID: 32241619 [TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B; J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881 [TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials. Yang P; Shen W; Chen X; Zhu D; Xu X; Wu T; Xu G; Wu Q Heart Fail Rev; 2019 Sep; 24(5):637-646. PubMed ID: 31030322 [TBL] [Abstract][Full Text] [Related]
20. Effects of the Non-Steroidal MRA Finerenone with and without Concomitant SGLT2 Inhibitor Use in Heart Failure. Vaduganathan M; Claggett BL; Kulac IJ; Miao ZM; Desai AS; Jhund PS; Henderson AD; Brinker M; Lay-Flurrie J; Viswanathan P; Scheerer MF; Lage A; Lam CSP; Senni M; Shah SJ; Voors AA; Zannad F; Pitt B; McMurray JJV; Solomon SD Circulation; 2024 Sep; ():. PubMed ID: 39340828 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]